VectorBuilder Honored with 2025 CDMO Leadership Award for CGT Global Category
VectorBuilder, a global leader in gene delivery and technology, proudly announces that it has been awarded the "CDMO Leadership Award - Cell & Gene Therapy, Global Category" in the annual selection jointly hosted by Outsourced Pharma and Life Science Connect. The award recognizes VectorBuilder’s performance in key areas such as quality, reliability, and technical capability.
“This award highlights VectorBuilder’s dedication to putting clients first while driving excellence in technical innovation and advanced manufacturing solutions,” said Dr. Bruce Lahn, Chief Scientist at VectorBuilder. “We are honored that our team’s dedication to advancing gene vector technologies and setting new standards in gene drug manufacturing is being recognized among industry leaders. From early-stage gene vector design to GMP manufacturing and regulatory support, we remain focused on delivering high-quality gene delivery solutions that help accelerate our clients’ path to commercialization.”
For the past fourteen years, the CDMO Leadership Awards have recognized top-performing contract development and manufacturing organizations based on industry research and sponsor feedback and offers drug developers insight into highly rated outsourcing partners.
“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Louis Garguilo, chief editor at Outsourced Pharma. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs.”
VectorBuilder operates approximately 10,000 m² of modern GMP facilities for gene drug manufacturing, fully compliant with ICH guidelines and EU regulatory standards. Equipped with over ten GMP manufacturing pipelines, the facility supports plasmid, AAV, lentivirus, and IVT mRNA manufacturing across a wide range of scales. In addition to GMP manufacturing, VectorBuilder also offers process development, analytical development, cell banking, fill/finish, and regulatory support. The company has provided IND-enabling vectors to a global client base across the US, Europe, Japan, China, and South Korea.